| Title | A Truncated IL-17RC Peptide Ameliorates Synovitis and Bone Destruction of Arthritic Mice |
| Authors | Du, Yuxuan Tong, Yulong Mei, Wentong Jia, Junhui Niu, Menglin Cao, Wei Lou, Weiwei Li, Shentao Li, Zhanguo Stinson, W. Alexander Yuan, Huihui Zhao, Wenming |
| Affiliation | Capital Med Univ, Sch Basic Med Sci, Dept Immunol, 10 Xitoutiao, Beijing 100069, Peoples R China. Aerosp Ctr Hosp, Dept Blood Transfus, 15 Yuquan Rd, Beijing 100049, Peoples R China. Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, Clin Immunol Ctr, 11 Xizhimen South St, Beijing 100044, Peoples R China. Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA. |
| Keywords | bone destruction collagen-induced arthritis (CIA) synovitis truncated IL-17RC peptides COLLAGEN-INDUCED ARTHRITIS NECROSIS-FACTOR-ALPHA RHEUMATOID-ARTHRITIS INTERLEUKIN-17 FAMILY JOINT INFLAMMATION MOUSE MODEL EXPRESSION RECEPTOR BLOCKADE CELLS |
| Issue Date | 2016 |
| Publisher | Advanced Healthcare Materials |
| Citation | Advanced Healthcare Materials.2016,5(22),2911-2921. |
| Abstract | Peptide-based therapy, such as modified peptides, has attracted increased attention. IL-17 is a promising therapeutic target for autoimmune diseases, and levels of circulating bioactive IL-17 are associated with rheumatoid arthritis severity. In this study, a modified truncated IL-17RC is generated to ameliorate inflammation and bone destruction in arthritis. The truncated IL-17RC binds to both IL-17A and IL-17F with higher binding capacity compared to nonmodified IL-17RC. In addition, the truncated IL-17RC reduces the secretion of inflammatory and osteoclastogenic factors induced by IL-17A/F in vitro. Moreover, the administration of truncated IL-17RC dramatically improves symptoms of inflammation and inhibited bone destruction in collagen-induced arthritis mice. Collectively, these data demonstrate that modified truncated IL-17RC peptide may be a more effective treatment strategy in the simultaneous inhibition of both IL-17A and IL-17F signaling, whereas the existing agents neutralize IL-17A or IL-17F alone. These suggest that the truncated IL-17RC may be a potential candidate in the treatment of inflammatory associated bone diseases. |
| URI | http://hdl.handle.net/20.500.11897/492681 |
| ISSN | 2192-2640 |
| DOI | 10.1002/adhm.201600668 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 人民医院 |
